Posted by Michael Wonder on 22 Aug 2023
Krystal Biotech announces sale of priority review voucher for $100 million
21 August 2023 - Krystal Biotech announced that it has completed the sale of its rare paediatric disease priority review voucher for $100 million.
The Company was awarded the voucher following the US FDA accelerated approval of Vyjuvtek (beremagene geperpavec-svdt) for the treatment of recessive or dominant dystrophic epidermolysis bullosa for patients 6 months of age and older.
